Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting with the Granisetron Transdermal System (GTDS): Three Clinical Perspectives on Three Case Studies in Solid Tumors

Journal of Supportive Oncology

Volumn 10, Issue SUPPL. 5, 2012, Pages

  Smith, Judith A ^a,b   Anastasia, Paula ^c   Rappaport, Marc ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d DANBURY HOSPITAL   (United States)

Author keywords

5 HT antagonists; Antiemetics; Chemotherapy; Granisetron; Nausea; Patient nonadherence; Transdermal administration; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FOSAPREPITANT; GRANISETRON; LONG ACTING DRUG; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PACLITAXEL; PALONOSETRON; PROCHLORPERAZINE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PARTIAL MASTECTOMY; PRESCRIPTION; PROPHYLAXIS; RADIATION DOSE; RISK ASSESSMENT; SENTINEL LYMPH NODE METASTASIS; SOLID TUMOR; TRANSDERMAL PATCH; TREATMENT DURATION; UTERINE CERVIX CANCER;

EID: 84866463521     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2012.07.001     Document Type: Article

References (51)

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Antiemesis v1.2012 July 20, 2011, National Comprehensive Cancer Network, National Comprehensive Cancer Network, Fort Washington, PA. http://www.nccn.org/.
2. Basch E., Prestrud A.A., Hesketh P.J., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29(31):4189-4198.
3. Kris M.G., Tonato M., Bria E., et al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2011, 19(suppl 1):S25-S32.
4. Einhorn L.H., Grunberg S.M., Rapoport B., Rittenberg C., Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2011, 19(suppl 1):S1-S4.
5. Roila F., Warr D., Aapro M., et al. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer 2011, 19(suppl 1):S57-S62.
6. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(suppl 5):v232-v243.
7. Roila F., Herrstedt J., Gralla R.J., Tonato M. Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: guideline update and results of the Perugia consensus conference. Support Care Cancer 2011, 19(suppl 1):S63-S65.
8. Kraut L., Fauser A.A. Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems. Drugs 2001, 61(11):1553-1562.
9. Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2009, 13(6):711-714.
10. Sancuso® (granisetron transdermal system) [package insert] August 2008, ProStrakan Inc., Bedminster, NJ.
11. Boccia R.V., Gordan L.N., Clark G., Howell J.D., Grunberg S.M. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011, 19(10):1609-1617.
12. Ballatori E., Roila F., Ruggeri B., et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 2007, 15(2):179-185.
13. Cohen L., de Moor C.A., Eisenberg P., Ming E.E., Hu H. Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2006, 15(5):497-503.
14. Fernández-Ortega P., Caloto M.T., Chirveches E., et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer 2012, [Epub ahead of print].
15. Haiderali A., Menditto L., Good M., Teitelbaum A., Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 2011, 19(6):843-851.
16. Ihbe-Heffinger A., Ehlken B., Bernard R., et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004, 15(3):526-536.
17. Hassan B.A., Yusoff Z.B. Negative impact of chemotherapy on breast cancer patients. Asian Pac J Cancer Prev 2010, 11(6):1523-1527.
18. Bloechl-Daum B., Deuson R.R., Mavros P., Hansen M., Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006, 24(27):4472-4478.
19. Booth C.M., Clemons M., Dranitsaris G., et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007, 5(8):374-380.
20. Shih V., Wan H.S., Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 2009, 43(3):444-452.
21. Lee J., Dibble S.L., Pickett M., Luce J. Chemotherapy-induced nausea/vomiting and functional status in women treated for breast cancer. Cancer Nurs 2005, 28(4):249-255.
22. Richardson J.L., Marks G., Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988, 6(11):1746-1752.
23. Gebbia V., Bellavia G., Ferrau F., Valerio M.R. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 2012, 11(suppl 1):S49-S59.
24. Saratsiotou I., Kordoni M., Bakogiannis C., et al. Treatment adherence of cancer patients to orally administered chemotherapy: insights from a Greek study using a self-reported questionnaire. J Oncol Pharm Pract 2011, 17(4):304-311.
25. Craver C., Gayle J., Balu S., Buchner D. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 2011, 14(1):87-98.
26. Dibble S.L., Isreal J., Nussey B., Casey K., Luce J. Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 2003, 30(2):E40-E47.
27. Valero V., Forbes J., Pegram M.D., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011, 29(2):149-156.
28. Hesketh P.J., Kris M.G., Grunberg S.M., et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997, 15(1):103-109.
29. Roscoe J.A., Morrow G.R., Colagiuri B., et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 2010, 18(7):869-876.
30. Cashman J., Wright J., Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer 2010, 18(5):651-655.
31. Maloney K.W., Kagan S.H. Adherence and oral agents with older patients. Semin Oncol Nurs 2011, 27(2):154-160.
32. Georgy A., Neceskas J., Goodin S. Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns. Am J Health Syst Pharm 2007, 64(21):2227-2236.
33. Kairuz T., Bye L., Birdsall R., et al. Identifying compliance issues with prescription medicines among older people: a pilot study. Drugs Aging 2008, 25(2):153-162.
34. Colagiuri B., Zachariae R. Patient expectancy and post-chemotherapy nausea: a meta-analysis. Ann Behav Med 2010, 40(1):3-14.
35. Roscoe J.A., Hickok J.T., Morrow G.R. Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med 2000, 22(2):121-126.
36. Bourdeanu L., Frankel P., Yu W., et al. Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Support Oncol 2012, 10(4):149-154.
37. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354(1):34-43.
38. Barlin J.N., Dao F., Zgheib N.B., et al. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2012, 125(3):621-624.
39. Gray H.J., Shah C.A., Swensen R.E., Tamimi H.K., Goff B.A. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol 2010, 116(3):340-344.
40. Aloxi® (palonsetron HCl) injection for intravenous use [package insert] 2009, Eisai Inc., Woodcliff Lake, NJ.
41. Eisenberg P., MacKintosh F.R., Ritch P., Cornett P.A., Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004, 15(2):330-337.
42. Decker G.M., DeMeyer E.S., Kisko D.L. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006, 4(1):35-41. 52.
43. Feinberg B.A., Gilmore J., Haislip S., Gondesen T., Saleh M.N., Hawke Lenz W. Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting. Comm Oncol 2009, 6(2):62-67.
44. Hatoum H.T., Lin S.J., Buchner D., Cox D. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice. Support Care Cancer 2012, 20(5):941-949.
45. Grote T., Hajdenberg J., Cartmell A., Ferguson S., Ginkel A., Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006, 4(8):403-408.
46. Schwartzberg L., Jackson J., Jain G., Balu S., Buchner D. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Expert Rev Pharmacoecon Outcomes Res 2011, 11(4):481-488.
47. Howell J., Smeets J., Drenth H.J., Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 2009, 15(4):223-231.
48. Grunberg S., Clark-Snow R.A., Koeller J. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management: Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. Support Care Cancer 2010, [Epub ahead of print].
49. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358(23):2482-2494.
50. Sun C.C., Bodurka D.C., Weaver C.B., et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005, 13(4):219-227.
51. Tina Shih Y.C., Xu Y., Elting L.S. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007, 110(3):678-685.